BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 38485271)

  • 1. Interrogating the Theranostic Capacity of a MUC16-Targeted Antibody for Ovarian Cancer.
    Mack KN; Samuels ZV; Carter LM; Viray TD; Mandleywala K; Brooks CL; Hollingsworth MA; Radhakrishnan P; Lewis JS
    J Nucl Med; 2024 Apr; 65(4):580-585. PubMed ID: 38485271
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ImmunoPET of Ovarian and Pancreatic Cancer with AR9.6, a Novel MUC16-Targeted Therapeutic Antibody.
    Sharma SK; Mack KN; Piersigilli A; Pourat J; Edwards KJ; Keinänen O; Jiao MS; Zhao H; White B; Brooks CL; de Stanchina E; Madiyalakan MR; Hollingsworth MA; Radhakrishnan P; Lewis JS; Zeglis BM
    Clin Cancer Res; 2022 Mar; 28(5):948-959. PubMed ID: 34907079
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Radiopharmacologic screening of antibodies to the unshed ectodomain of MUC16 in ovarian cancer identifies a lead candidate for clinical translation.
    Nemieboka B; Sharma SK; Rao TD; Edwards KJ; Yan S; Wang P; Ragupathi A; Piersigilli A; Spriggs DR; Lewis JS
    Nucl Med Biol; 2020; 86-87():9-19. PubMed ID: 32403071
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PET imaging of HER1-expressing xenografts in mice with 86Y-CHX-A''-DTPA-cetuximab.
    Nayak TK; Regino CA; Wong KJ; Milenic DE; Garmestani K; Baidoo KE; Szajek LP; Brechbiel MW
    Eur J Nucl Med Mol Imaging; 2010 Jul; 37(7):1368-76. PubMed ID: 20155263
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preclinical 89Zr Immuno-PET of High-Grade Serous Ovarian Cancer and Lymph Node Metastasis.
    Sharma SK; Sevak KK; Monette S; Carlin SD; Knight JC; Wuest FR; Sala E; Zeglis BM; Lewis JS
    J Nucl Med; 2016 May; 57(5):771-6. PubMed ID: 26837339
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preclinical Characterization of the
    Striese F; Neuber C; Gräßel S; Arndt C; Ullrich M; Steinbach J; Pietzsch J; Bergmann R; Pietzsch HJ; Sihver W; Frenz M; Feldmann A; Bachmann MP
    Int J Mol Sci; 2023 May; 24(11):. PubMed ID: 37298374
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Radiolabeled Antibodies Against Müllerian-Inhibiting Substance Receptor, Type II: New Tools for a Theranostic Approach in Ovarian Cancer.
    Deshayes E; Ladjohounlou R; Le Fur P; Pichard A; Lozza C; Boudousq V; Sevestre S; Jarlier M; Kashani R; Koch J; Sosabowski J; Foster J; Chouin N; Bruchertseifer F; Morgenstern A; Kotzki PO; Navarro-Teulon I; Pouget JP
    J Nucl Med; 2018 Aug; 59(8):1234-1242. PubMed ID: 29674421
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preparation of
    Pandey U; Kameswaran M; Gamre N; Dash A
    J Labelled Comp Radiopharm; 2019 Apr; 62(4):158-165. PubMed ID: 30663095
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PET imaging of tumor angiogenesis in mice with VEGF-A-targeted (86)Y-CHX-A″-DTPA-bevacizumab.
    Nayak TK; Garmestani K; Baidoo KE; Milenic DE; Brechbiel MW
    Int J Cancer; 2011 Feb; 128(4):920-6. PubMed ID: 20473899
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structural Basis for Multivalent MUC16 Recognition and Robust Anti-Pancreatic Cancer Activity of Humanized Antibody AR9.6.
    Aguilar EN; Sagar S; Murray BR; Rajesh C; Lei EK; Michaud SA; Goodlett DR; Caffrey TC; Grandgenett PM; Swanson B; Brooks TM; Black AR; van Faassen H; Hussack G; Henry KA; Hollingsworth MA; Brooks CL; Radhakrishnan P
    Mol Cancer Ther; 2024 Feb; ():. PubMed ID: 38394685
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Zirconium-89 labeled panitumumab: a potential immuno-PET probe for HER1-expressing carcinomas.
    Bhattacharyya S; Kurdziel K; Wei L; Riffle L; Kaur G; Hill GC; Jacobs PM; Tatum JL; Doroshow JH; Kalen JD
    Nucl Med Biol; 2013 May; 40(4):451-7. PubMed ID: 23454247
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of [
    Tsai WK; Zettlitz KA; Dahlbom M; Reiter RE; Wu AM
    Mol Imaging Biol; 2020 Oct; 22(5):1380-1391. PubMed ID: 32661830
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Leveraging a Dual Variable Domain Immunoglobulin to Create a Site-Specifically Modified Radioimmunoconjugate.
    MacPherson DS; Hwang D; Sarrett SM; Keinänen O; Rodriguez C; Rader C; Zeglis BM
    Mol Pharm; 2023 Jan; 20(1):775-782. PubMed ID: 36377696
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preclinical evaluation of the theranostic potential of
    Wu Y; Li T; Zhang X; Jing H; Li F; Huo L
    EJNMMI Radiopharm Chem; 2024 Jan; 9(1):5. PubMed ID: 38194043
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhanced efficacy of radioimmunotherapy with 90Y-CHX-A''-DTPA-hu3S193 by inhibition of epidermal growth factor receptor (EGFR) signaling with EGFR tyrosine kinase inhibitor AG1478.
    Lee FT; Mountain AJ; Kelly MP; Hall C; Rigopoulos A; Johns TG; Smyth FE; Brechbiel MW; Nice EC; Burgess AW; Scott AM
    Clin Cancer Res; 2005 Oct; 11(19 Pt 2):7080s-7086s. PubMed ID: 16203806
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative
    Sharma R; Kameswaran M; Dash A
    Cancer Biother Radiopharm; 2020 Apr; 35(3):177-189. PubMed ID: 32196365
    [No Abstract]   [Full Text] [Related]  

  • 17. A Mucin 16 bispecific T cell-engaging antibody for the treatment of ovarian cancer.
    Crawford A; Haber L; Kelly MP; Vazzana K; Canova L; Ram P; Pawashe A; Finney J; Jalal S; Chiu D; Colleton CA; Garnova E; Makonnen S; Hickey C; Krueger P; DelFino F; Potocky T; Kuhnert J; Godin S; Retter MW; Duramad P; MacDonald D; Olson WC; Fairhurst J; Huang T; Martin J; Lin JC; Smith E; Thurston G; Kirshner JR
    Sci Transl Med; 2019 Jun; 11(497):. PubMed ID: 31217340
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design, synthesis, and preclinical evaluation of a novel bifunctional macrocyclic chelator for theranostics of cancers.
    Xu J; Cai F; Luo Z; Fan W; Dai J; Cui J; Li S; Geng C; Zheng Q; Wang Z; Tang X
    Eur J Nucl Med Mol Imaging; 2022 Jul; 49(8):2618-2633. PubMed ID: 35347438
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of [(111/114m)In]CHX-A''-DTPA-ZHER2:342, an affibody ligand coniugate for targeting of HER2-expressing malignant tumors.
    Orlova A; Rosik D; Sandström M; Lundqvist H; Einarsson L; Tolmachev V
    Q J Nucl Med Mol Imaging; 2007 Dec; 51(4):314-23. PubMed ID: 17464277
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A comparative evaluation of the chelators H4octapa and CHX-A″-DTPA with the therapeutic radiometal (90)Y.
    Price EW; Edwards KJ; Carnazza KE; Carlin SD; Zeglis BM; Adam MJ; Orvig C; Lewis JS
    Nucl Med Biol; 2016 Sep; 43(9):566-576. PubMed ID: 27419360
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.